Overall, the interaction of the two proteins seems to occur in a colon cancer scenario regardless of p53 protein status, which could be exploited as a therapeutic opportunity for targeting ERRα in different cancer-related mutant forms of p53. The gene discussed is ESRRA; the disease is malignant colon neoplasm.